Key result
Bipolar steroid-eluting epicardial leads are linked to ~87% better 48-month survival vs unipolar nonsteroid-eluting leads.
Why the study?
Given recent advances in epicardial lead subtypes, investigating their long-term function was essential.
Do bipolar steroid-eluting epicardial leads improve 48-month lead survival compared to unipolar nonsteroid-eluting leads in patients undergoing epicardial pacemaker implantation?
Cohort (n=77)
No
Do bipolar steroid-eluting epicardial leads improve 48-month lead survival compared to unipolar nonsteroid-eluting leads in patients undergoing epicardial pacemaker implantation?
Effect estimate: HR 0.13 (95% CI 0.02-0.99)
p-value: p=0.049
Bipolar steroid-eluting epicardial leads demonstrate superior 48-month survival and more stable pacing thresholds compared to unipolar nonsteroid-eluting leads.
No takes yet. Share an insight, caveat, or question.
Bipolar steroid-eluting leads were associated with better survival; leaves open preference in epicardial pacing without randomized data.
Fazelifar et al. (2022) conducted a cohort in epicardial lead implantation (n=77). Bipolar steroid-eluting epicardial leads vs. Unipolar nonsteroid-eluting epicardial leads was evaluated on 48-month survival (HR 0.13, 95% CI 0.02-0.99, p=0.049). Bipolar steroid-eluting epicardial leads demonstrated significantly better 48-month survival compared to unipolar nonsteroid-eluting leads (HR 0.13; 95% CI 0.02-0.99; p=0.049).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: